Clinical Usefulness of Cell-based Indirect Immunofluorescence Assay for the Detection of Aquaporin-4 Antibodies in Neuromyelitis Optica Spectrum Disorder
1
조회
0
다운로드
7
인용
0
참고문헌
키워드
초록
Background: The presence of antibodies to aquaporin-4 (AQP4) has been identified as a key characteristic of neuromyelitis optica spectrum disorder (NMOSD), an autoimmune inflammatory demyelinating central nervous system (CNS) disorder. We evaluated the performance of a cell-based indirect immunofluorescence assay (CIIFA) for detecting AQP4 antibodies using antigen prepared with a recombinant AQP4 peptide transfection technique and assessed the usefulness of CIIFA for diagnosis of NMOSD in routine clinical practice. Methods: Forty-six serum samples from 36 patients as a comparison set and another 101 patients enrolled consecutively from a neurology clinic were included. CIIFA and fluorescence immunoprecipitation assays (FIPA) were performed. CIIFA was performed at 2 different institutions for comparison purposes. Results: CIIFA and FIPA sensitivity in the comparison set was 86% and 79% in neuromyelitis optica (NMO) patients and 55% and 36% in high-risk NMO patients, respectively. The semiquantitative titer measured by CIIFA correlated well with the arbitrary unit (fluorescence units [FU]) derived from FIPA (r=0.66). Titers measured by CIIFA and FIPA were elevated in NMO patients compared to high-risk NMO patients (1:240 vs. 1:180 and 8,390 vs. 4,059FU, respectively). The frequency of AQP4 antibody detection by CIIFA in 101 consecutively enrolled patients was 100% in NMO and 23% in high-risk NMO patients, while only 4.6% in control patients, including those with multiple sclerosis. Conclusions: Detection of AQP4 antibodies by CIIFA provides sensitive and highly specific diagnostic information for NMO and high-risk NMO patients, which can be used to differentiate these conditions from other demyelinating CNS diseases.
Abstract
Background: The presence of antibodies to aquaporin-4 (AQP4) has been identified as a key characteristic of neuromyelitis optica spectrum disorder (NMOSD), an autoimmune inflammatory demyelinating central nervous system (CNS) disorder. We evaluated the performance of a cell-based indirect immunofluorescence assay (CIIFA) for detecting AQP4 antibodies using antigen prepared with a recombinant AQP4 peptide transfection technique and assessed the usefulness of CIIFA for diagnosis of NMOSD in routine clinical practice. Methods: Forty-six serum samples from 36 patients as a comparison set and another 101 patients enrolled consecutively from a neurology clinic were included. CIIFA and fluorescence immunoprecipitation assays (FIPA) were performed. CIIFA was performed at 2 different institutions for comparison purposes. Results: CIIFA and FIPA sensitivity in the comparison set was 86% and 79% in neuromyelitis optica (NMO) patients and 55% and 36% in high-risk NMO patients, respectively. The semiquantitative titer measured by CIIFA correlated well with the arbitrary unit (fluorescence units [FU]) derived from FIPA (r=0.66). Titers measured by CIIFA and FIPA were elevated in NMO patients compared to high-risk NMO patients (1:240 vs. 1:180 and 8,390 vs. 4,059FU, respectively). The frequency of AQP4 antibody detection by CIIFA in 101 consecutively enrolled patients was 100% in NMO and 23% in high-risk NMO patients, while only 4.6% in control patients, including those with multiple sclerosis. Conclusions: Detection of AQP4 antibodies by CIIFA provides sensitive and highly specific diagnostic information for NMO and high-risk NMO patients, which can be used to differentiate these conditions from other demyelinating CNS diseases.
참고문헌 (31)
- Devic E., "Subacute myelitis complicated by optic neuritis", Bull Med, 8, pp.1033~1034 (1894)
- Wingerchuk DM, "The clinical course of neuromyelitis optica (Devic’s syndrome)", Neurology, 53, pp.1107~1114 (1999)
- de Seze J, "Devic’s neuromyelitis optica: clinical, laboratory, MRI and outcome profile", J Neurol Sci, 197, pp.57~61 (2002)
- Wingerchuk DM, "The spectrum of neuromyelitis optica", Lancet Neurol, 6, pp.805~815 (2007)
- Kira J., "Multiple sclerosis in the Japanese population", Lancet Neurol, 2, pp.117~127 (2003)
- Matsushita T, "Aquaporin-4 autoimmune syndrome and anti-aquaporin-4 antibodynegative opticospinal multiple sclerosis in Japanese", Mult Scler, 15, pp.834~847 (2009)
- Lennon V, "A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis", Lancet, 364, pp.2106~2112 (2004)
- Lennon VA, "IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel", J Exp Med, 202, pp.473~477 (2005)
- Hiroaki Y, "Implications of the aquaporin-4 structure on array formation and cell adhesion", J Mol Biol, 355, pp.628~639 (2005)
- Paul F, "Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica", PLoS Med, 4, pp.e133~ (2007)
- Papeix C, "Immunosuppressive therapy is more effective than interferon in neuromyelitis optica", Mult Scler, 13, pp.256~259 (2007)
- Cree BA, "An open label study of the effects of rituximab in neuromyelitis optica", Neurology, 64, pp.1270~1272 (2005)
- Keegan M, "Plasma exchange for severe attacks of CNS demyelination: predictors of response", Neurology, 58, pp.143~146 (2002)
- Jarius S, "AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance", Nat Rev Neurol, 6, pp.383~392 (2010)
- Waters P, "Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays", Int MS J, 15, pp.99~105 (2008)
- Jarius S, "Standardized methods for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen", J Neurol Sci, 291, pp.52~56 (2010)
- Hayakawa S, "Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay", J Neuroimmunol, 196, pp.181~187 (2008)
- Takahashi T, "Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre", Brain, 130, pp.1235~1243 (2007)
- Wingerchuk DM, "Revised diagnostic criteria for neuromyelitis optica", Neurology, 66, pp.1485~1489 (2006)
- Waters P, "Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis", Arch Neurol, 65, pp.913~919 (2008)
- Lucchinetti CF, "A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica", Brain, 125, pp.1450~1461 (2002)
- Takahashi T, "Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica", Tohoku J Exp Med, 210, pp.307~313 (2006)
- Fazio R, "Antiacquaporin 4 antibodies detection by different techniques in neuromyelitis optica patients", Mult Scler, 15, pp.1153~1163 (2009)
- De Vidi I, "Strategy for anti-aquaporin-4 auto-antibody identification and quantification using a new cell-based assay", Clin Immunol, 138, pp.239~246 (2011)
- Hinson SR, "Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells", Arch Neurol, 66, pp.1164~1167 (2009)
- McKeon A, "Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays", Arch Neurol, 66, pp.1134~1138 (2009)
- Pittock SJ, "Neuromyelitis optica and non organ-specific autoimmunity", Arch Neurol, 65, pp.78~83 (2008)
- Jarius S, "Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders", Mult Scler, 17, pp.1067~1073 (2011)
- Hinson SR, "Neurological autoimmunity targeting aquaporin-4", Neuroscience, 168, pp.1009~1018 (2010)
- Min JH, "Brain abnormalities in Sjogren syndrome with recurrent CNS manifestations: association with neuromyelitis optica", Mult Scler, 15, pp.1069~1076 (2009)
- Jarius S, "Antibody to aquaporin-4 in the long-term course of neuromyelitis optica", Brain, 131, pp.3072~3080 (2008)